Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
A gender gap in autoimmunity.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Studying both sexes: a guiding principle for biomedicine.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Power estimation for non-standardized multisite studies.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Extension CombiRx data show no benefit of combined MS drugs
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.

Pages